Novartis Loses First Zometa Trial, Must Pay $3.2M
Novartis Pharmaceutical Corp. has lost the bellwether trial over its bone cancer drug Zometa, with a Montana jury awarding $3.2 million to a woman who accused the company of failing to...To view the full article, register now.
Already a subscriber? Click here to view full article